immunotherapy

by Karen Guzman, Yale University edited by Lisa Lock, reviewed by Robert Egan  Editors’ notes  The GIST Add as preferred source AI-generated image. Credit: Sidi Chen Since scientists first discovered that human immune cells could be modified to become cancer-fighting agents, they’ve been trying to engineer a cell that’s effective against solid tumors, which account for the vast […]

by Wellcome Trust Sanger Institute edited by Gaby Clark, reviewed by Robert Egan  Editors’ notes  The GIST Add as preferred source Graphical abstract. Credit: Cell Reports Medicine (2026). DOI: 10.1016/j.xcrm.2025.102565 The deletion of two cancer genes, CHD1 and MAP3K7, improves how well tumors respond to cancer immunotherapy and could be used as biomarkers to help predict which patients are most

by Aubrey Bloom, University of Texas MD Anderson Cancer Center edited by Stephanie Baum, reviewed by Robert Egan  Editors’ notes  The GIST Add as preferred source Credit: Unsplash/CC0 Public Domain According to a Phase I study led by researchers at The University of Texas MD Anderson Cancer Center, published in Nature Medicine, the novel monoclonal antibody linavonkibart has demonstrated the potential

by Weizmann Institute of Science edited by Sadie Harley, reviewed by Andrew Zinin  Editors’ notes Credit: Pixabay/CC0 Public Domain One of the most challenging moments in cancer treatment comes when a therapy stops working. In many metastatic cancers, drugs that are initially effective lose their potency over time, as malignant cells acquire mutations that enable them to survive

by University of Chicago Medical Center edited by Lisa Lock, reviewed by Robert Egan  Editors’ notes Credit: Cancer Cell (2025). DOI: 10.1016/j.ccell.2025.11.001 Immunotherapy has revolutionized cancer care by training the immune system to detect and destroy tumors. For many patients, it works very well in shrinking tumors and sending cancer into remission, an undetectable state of cancer. But that remission

by Dana-Farber Cancer Institute edited by Sadie Harley, reviewed by Andrew Zinin  Editors’ notes Graphical abstract. Credit: Immunity (2025). DOI: 10.1016/j.immuni.2025.10.013 Immunotherapy with immune checkpoint inhibitors is standard first-line treatment for advanced renal cell carcinoma (RCC), but not every patient responds. An open question is whether specific patterns of immune signaling, specifically interferon signaling, influence the effectiveness of immune checkpoint

by Naedine Hazell, Yale University edited by Lisa Lock, reviewed by Andrew Zinin  Editors’ notes Anti–PD-1/anti-MIF improves survival and tumor responses. Credit: JCI Insight (2025). DOI: 10.1172/jci.insight.191539 Promising study in dual inhibition of PD1 and macrophage migration inhibitory factor Two therapies can be better than one for treating some cancers, concludes a Yale study published Oct. 22 in JCI Insight that finds promise in